Celadon Pharmaceuticals Plc
("Celadon" or the "Company")
Notification of transactions by persons discharging managerial responsibility
London, 10 February 2023 - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the research, cultivation, manufacturing and sale of breakthrough cannabis-based medicines, announces that an award of options to acquire the Company's shares for their nominal value of £0.01 was granted to an Executive Director on 9 February 2023 under the Company's Long Term Incentive Plan ("LTIP") as shown below. The Options will vest on the third anniversary of grant on 9 February 2026, subject to the achievement of performance criteria. Once vested, the awards must be held for two years.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Jonathan Turner | ||||
| 2 | Reason for the notification | |||||
| a) | Position / status | PDMR - Chief Financial Officer | ||||
| b) | Initial notification / Amendment | Initial Notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Celadon Pharmaceuticals plc | ||||
| b) | LEI | 213800YXCATORT475807 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.01 GB00BDQYGP38 | ||||
| b) | Nature of the transaction | Award over nominal cost options under the Celadon Pharmaceuticals plc Long Term Incentive Plan | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price | N/A Single Transaction | ||||
| e) | Date of the transaction | 9 February 2023 | ||||
| f) | Place of the transaction | London | ||||
Enquiries:
| Celadon Pharmaceuticals Plc |
|
| James Short Jonathan Turner Arthur Wakeley | Via Powerscourt |
|
|
|
| Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
| Bobbie Hilliam / Andrew Potts / Patrick Dolaghan | +44 (0)20 7523 8000 |
| | |
| Powerscourt Group | |
| Sarah MacLeod / Nick Johnson / Sam Austrums / Ibrahim Khalil | +44 (0)20 7250 1446
|
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility operates to an EU-GMP standard and comprises indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. The Company's subsidiary, LVL, owns a MHRA conditionally-approved clinical trial using cannabis based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics which is developing a licenced cannabinoid medicine to treat children with Autism Spectrum Disorder.
For further information please visit our website www.celadonpharma.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.